Navigation Links
Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
Date:10/6/2008

ubject to risks and uncertainties surrounding the efficacy of PROVENGE to treat men suffering from prostate cancer, risks and uncertainties surrounding the presentation of data to the FDA and approval of product applications by the FDA and risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such differences include risks related to our limited operating history, risks associated with completing our clinical trials, the risk that the safety and/or efficacy results of existing clinical trials or from additional clinical trials for PROVENGE will not support approval for a biologics license, the risk that the FDA may interpret data differently than we do or require more data or a more rigorous analysis of data than expected, the risk that the FDA will not approve a product for which a biologics license has been applied, the risk that the results of a clinical trial for PROVENGE or other product may not be indicative of results obtained in a later clinical trial, risks that we may lack the financial resources and access to capital to fund required clinical trials or commercialization of PROVENGE, our dependence on the efforts of third parties, and our dependence on intellectual property. Further information on the factors and risks that could affect Dendreon's business, financial condition and results of

operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov.


'/>"/>
SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
2. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
3. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
4. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
5. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
6. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. The Childrens Hospital of Philadelphia Announces New Regional Participant in The National Childrens Study
9. Lilly Announces Initiation of Second Global Phase III Trial of Investigational Alzheimers Disease Compound
10. Resurgent Health and Medical Announces That Childrens Hospitals and Clinics of Minnesota has Ordered 25 CleanTech Automated Handwashing Systems
11. Bioheart Announces 35 Leading U.S. Heart Failure Centers Engaged in Phase II/III Marvel Trial of Myogenic Cells for Treating Advanced Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... PARIS , July 30, 2014 /PRNewswire/ ... Sanofi (EURONEXT: SAN and NYSE: SNY ) ... of alirocumab in people with hypercholesterolemia met their primary ... in low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared ... monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). ...
(Date:7/30/2014)... July 30, 2014  Packaging Coordinators, Inc. (PCI) is ... to acquire Penn Pharmaceutical Services Limited (Penn Pharma). Penn Pharma ... in the United Kingdom and ... and Tokyo , Japan. Penn ... Clinical and Commercial dosage form manufacturing, as well as ...
(Date:7/30/2014)... FOREST, Ill., July 30, 2014  Hospira, Inc. ... provider of injectable drugs and infusion technologies, today ... 30, 2014. Net sales for the quarter were ... were $0.72. (Adjusted* measures exclude specified items as ... attached schedules.) On a U.S. Generally Accepted Accounting ...
Breaking Medicine Technology:Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8PCI Announces Definitive Agreement to Acquire Penn Pharma 2PCI Announces Definitive Agreement to Acquire Penn Pharma 3PCI Announces Definitive Agreement to Acquire Penn Pharma 4PCI Announces Definitive Agreement to Acquire Penn Pharma 5Hospira Reports Second-Quarter 2014 Results 2Hospira Reports Second-Quarter 2014 Results 3Hospira Reports Second-Quarter 2014 Results 4Hospira Reports Second-Quarter 2014 Results 5Hospira Reports Second-Quarter 2014 Results 6Hospira Reports Second-Quarter 2014 Results 7Hospira Reports Second-Quarter 2014 Results 8Hospira Reports Second-Quarter 2014 Results 9Hospira Reports Second-Quarter 2014 Results 10Hospira Reports Second-Quarter 2014 Results 11Hospira Reports Second-Quarter 2014 Results 12Hospira Reports Second-Quarter 2014 Results 13Hospira Reports Second-Quarter 2014 Results 14Hospira Reports Second-Quarter 2014 Results 15Hospira Reports Second-Quarter 2014 Results 16Hospira Reports Second-Quarter 2014 Results 17Hospira Reports Second-Quarter 2014 Results 18Hospira Reports Second-Quarter 2014 Results 19Hospira Reports Second-Quarter 2014 Results 20Hospira Reports Second-Quarter 2014 Results 21Hospira Reports Second-Quarter 2014 Results 22Hospira Reports Second-Quarter 2014 Results 23Hospira Reports Second-Quarter 2014 Results 24Hospira Reports Second-Quarter 2014 Results 25
... COLLEGEVILLE, Pa., July 27 ... WYE ), announced the publication in Fertility and Sterility ... showed that the investigational compound bazedoxifene/conjugated estrogens (BZA/CE) significantly reduced ... of vaginal atrophy when compared to placebo. In this study, ...
... , , ENGLEWOOD CLIFFS, ... all regular body washes caused dry skin damage. Now, ... while cleansing with body wash. Current body washes actually damage ... to the loss of critical moisture. Recognizing skin lipids require ...
Cached Medicine Technology:Wyeth Reports Publication of Phase 3 Data for Bazedoxifene/Conjugated Estrogens, an Investigational Compound Being Studied for the Treatment of Menopausal Symptoms 2Wyeth Reports Publication of Phase 3 Data for Bazedoxifene/Conjugated Estrogens, an Investigational Compound Being Studied for the Treatment of Menopausal Symptoms 3Wyeth Reports Publication of Phase 3 Data for Bazedoxifene/Conjugated Estrogens, an Investigational Compound Being Studied for the Treatment of Menopausal Symptoms 4Wyeth Reports Publication of Phase 3 Data for Bazedoxifene/Conjugated Estrogens, an Investigational Compound Being Studied for the Treatment of Menopausal Symptoms 5Wyeth Reports Publication of Phase 3 Data for Bazedoxifene/Conjugated Estrogens, an Investigational Compound Being Studied for the Treatment of Menopausal Symptoms 6Video: New Dove(R) Body Washes with NutriumMoisture(TM) Restore Skin's Natural Moisture 2Video: New Dove(R) Body Washes with NutriumMoisture(TM) Restore Skin's Natural Moisture 3Video: New Dove(R) Body Washes with NutriumMoisture(TM) Restore Skin's Natural Moisture 4
(Date:7/30/2014)... York, NY (PRWEB) July 30, 2014 The ... nutrition school, is pleased to announce that Arianna Huffington has ... the curriculum of the Health Coach Training Program . ... The Huffington Post, a world-renowned news and blogging site that ... is the author of fourteen books and was included on ...
(Date:7/30/2014)... NY (PRWEB) July 30, 2014 Frozen shoulder ... are more likely to develop this nasty condition which occurs ... 60, and can last up to two and half years ... as frozen shoulder, and with good reason: it can render ... shirt — that is, if you aren't in too much ...
(Date:7/30/2014)... Amy Norton HealthDay Reporter ... in a garden might help soothe the agitation that commonly ... at 17 past studies, British researchers found evidence that watering ... soothe some dementia patients, anxiety. The study authors cautioned ... tough subject to study -- and the evidence of a ...
(Date:7/30/2014)... three months or more as babies have a ... cardiovascular and metabolic diseases, according to research from ... Louis. , "This study shows that birthweight and ... later," said Molly W. Metzger, PhD, assistant professor ... the study with Thomas W. McDade, PhD, of ...
(Date:7/30/2014)... Lauderdale, FL (PRWEB) July 30, 2014 Everyone ... and communication for basically everyone. Whether people are looking for ... for something like a dentist, the internet is pretty much ... precisely why Sierra Dental in Lauderdale Florida is so happy ... will bring their web presence into the modern age. Whether ...
Breaking Medicine News(10 mins):Health News:Arianna Huffington Joins Integrative Nutrition as a Guest Speaker 2Health News:Arianna Huffington Joins Integrative Nutrition as a Guest Speaker 3Health News:Good News for Diabetics Suffering from Frozen Shoulder 2Health News:Good News for Diabetics Suffering from Frozen Shoulder 3Health News:Good News for Diabetics Suffering from Frozen Shoulder 4Health News:Gardens a Center of Calm for People With Dementia 2Health News:Gardens a Center of Calm for People With Dementia 3Health News:Birthweight and breastfeeding have implications for children's health decades later 2Health News:Sierra Dental Releases New Website For Fort Lauderdale Residents 2
... URAC CEO joins company along with ... Chief Medical Officer, ANNAPOLIS, Md., ... management leaders to head the,growing healthcare consulting and technology company. Senior management ... -- Joel V. Brill, MD, AGAF FASGE FACG CHCQM, Chief Medical ...
... Philadelphia, PA, September 20, 2007 Mark Twain boasted that it ... We now may have the beginnings of understanding why some ... are in treatment for this problem. According to statistics provided ... is the leading preventable cause of death in the United States, ...
... save years in research that aligns patients ... Fla., Sept. 20 The,H. Lee Moffitt ... Azyxxi(R),the Microsoft(R) unified health enterprise platform, to ... programs. Azyxxi will be used,to assimilate large ...
... Calif., Sept. 20 /PRNewswire-FirstCall/-- DURECT Corporation,(Nasdaq: DRRX ... CEO, will,present at the UBS Global Life Sciences ... 1:30 p.m. Eastern Time. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ... presentation will be available by accessing,DURECT,s homepage at ...
... Healthcare Group,Inc. (OTC Bulletin Board: SNVH), today announced that ... notional principal amount of its,6.5% senior convertible promissory notes, ... purchase warrants. This sale was effected as the,initial part ... in the,aggregate notional principal amount of up to $5 ...
... Childrens Hospital of Pittsburgh of UPMC psychiatrist Eva M. Szigethy, ... have been chosen by the director of the National Institutes ... , NIH director Elias A. Zerhouni, MD, announced today that ... in the early stages of their careers, including Dr. Szigethy ...
Cached Medicine News:Health News:Schooner Healthcare Services, LLC Announces New Leadership Team 2Health News:Genetic variation affects smoking cessation treatment 2Health News:Moffitt Selects Microsoft's Azyxxi to Help Drive Personalized Cancer Treatment 2Health News:Synova Completes Sale of $3.3 Million in Senior Convertible Notes and Warrants 2Health News:Synova Completes Sale of $3.3 Million in Senior Convertible Notes and Warrants 3Health News:Children's Hospital of Pittsburgh psychiatrist receives prestigious NIH award 2
Triturus® is an open and completely automated ELISA immunoassay analyzer which can perform a variety of different tests on a series of samples and process several batches simultaneously....
... The current available techniques for prenatal diagnosis ... with their use a small but significant ... current standard care offers invasive prenatal baby ... risk of chromosomal or genetic abnormalities are ...
Custom Pediatric Nebulizer Assembly W/Tubing...
... the only HER-2 assessment test approved by ... for three claims: prognosis, adriamycin-based chemotherapy selection ... PathVysion is the only FISH-based DNA probe ... insert as an appropriate test to aid ...
Medicine Products: